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Objective: Proinflammatory cytokines are known to play roles in ischemia-reperfu-
sion injury of the heart, kidney, small bowel, skin, and liver. Little is known about
their roles in ischemia-reperfusion injury of the lung. This study was undertaken to
define the role of 2 proinflammatory cytokines, tumor necrosis factor  and
interleukin 1, in ischemia-reperfusion injury of the lung.
Methods: Left lungs of male rats were rendered ischemic for 90 minutes and
reperfused for up to 4 hours. Treated animals received anti-tumor necrosis factor 
or anti-interleukin 1 antibody before reperfusion. Increased vascular permeability
in the lung was measured by using iodine 125-labeled bovine serum albumin.
Neutrophil sequestration in the lung parenchyma was determined on the basis of
activity. Bronchoalveolar lavage was performed to measure cell counts. Separate
tissue samples were processed for histology, cytokine protein, and messenger RNA
content by using Western blotting and the ribonuclease protection assay.
Results: Animals receiving anti-tumor necrosis factor  and anti-interleukin 1 dem-
onstrated reduced injury compared with that seen in positive control animals (vascular
permeability of 48.7% and 29.4% lower, respectively; P  .001). Vascular injury was
reduced by 71% when antibodies to tumor necrosis factor  and interleukin 1 were
administered together. Lung neutrophil accumulation was markedly reduced among
animals receiving anti-tumor necrosis factor  and anti-interleukin 1 (myeloperoxidase
content of 30.9% and 38.5% lower, respectively; P  .04) and combination blockade
afforded even greater protection (52.4% decrease, P  .01). Bronchoalveolar lavage
leukocyte content was also reduced by treatment with anti-tumor necrosis factor ,
anti-interleukin 1, and combination treatment. Reductions in permeability, myeloper-
oxidase, and bronchoalveolar lavage leukocyte content also resulted in a decrease in a
histologic injury. Finally, anti-tumor necrosis factor  and anti-interleukin 1 treatment
resulted in decreased messenger RNA expression for a number of early response and
regulatory cytokines.
Conclusion: Tumor necrosis factor  and interleukin 1 help regulate the develop-
ment of lung ischemia-reperfusion injury. They appear to promote injury by altering
expression of proinflammatory and anti-inflammatory cytokines and influencing
tissue neutrophil recruitment.
Two of the most frequently studied cytokines in models of acuteinflammatory injury models are tumor necrosis factor  (TNF-) andinterleukin 1 (IL-1). These 2 proteins have a variety of proin-flammatory activities that have led to both scientific and clinicalinvestigations of their functional roles. TNF- is a 17-kd, 157-amino-acid cytokine that is secreted by a wide spectrum of cells,
including macrophages, monocytes, T cells, natural killer cells, and neutrophils.
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IL-1 is a 17-kd, 153-amino-acid protein that is predomi-
nantly produced by monocytes and macrophages, although
secretion from keratinocytes, endothelial cells, neutrophils,
fibroblasts, and smooth muscle cells has been demonstrated.
Both of these cytokines have an assortment of proinflam-
matory activities, including leukocyte chemoattraction,
phagocyte stimulation, enhancement of downstream cyto-
kine and chemokine production, and variable effects on cell
growth and death.
These cytokines have been studied in isolation and in
combination in multiple models of ischemia-reperfusion
injury in an variety of vascular beds. Functional roles for
TNF- and IL-1 have been identified in liver,1,2 heart,3,4
brain,5 kidney,6 hind limb,7 and gut8 ischemia and reperfu-
sion. These studies have demonstrated that TNF- and, to a
lesser extent, IL-1 promote injury in these vascular beds
and that blockade of these cytokines decreases injury in a
neutrophil-dependent manner. In addition to the local ef-
fects of these cytokines, secondary lung injury has also been
investigated in the liver,9 intestine,10 and hind limb.7 TNF-
promotes the generation of acute lung injury in all 3 of these
vascular beds. Investigations of hind limb ischemia and
reperfusion have demonstrated protection afforded by IL-1
receptor blockade.7
Studies of the roles of these 2 cytokines in acute non-
ischemic lung injury have been predominantly focused on
inflammatory injury induced by lipopolysaccharide,11 IgG
immune complex,12 and antiglomerular basement mem-
brane antibody.13 These studies have defined functional
roles for TNF- and IL-1 in each of these neutrophil-
dependent models. The degree of protection afforded by
blockade of either TNF- or IL-1 is between 40% and
60%. The ability of the recombinant preparations of these 2
cytokines to directly cause lung injury has also been dem-
onstrated and appears to be dependent on neutrophil recruit-
ment.14
Surprisingly little work has investigated the roles of
TNF- and IL-1 in direct lung ischemia-reperfusion in-
jury. Khimenko and colleagues15 examined the effects of
ventilated and nonventilated ischemia in an isolated buffer-
perfused rat lung. Interpretation of these studies is difficult
because they involve the use of isolated lung preparations,
nonphysiologic perfusate, and brief ischemia-reperfusion
periods. Despite these limitations, the authors were able to
correlate increased injury with higher levels of TNF- pro-
tein in the lung effluent. Other investigators have demon-
strated a functional role for TNF- in injury, which devel-
ops after 30 minutes and 4 hours of reperfusion. However,
there was significant variability in positive control animals
and inconsistent effects on collateral cytokine expression.16
Chang and coworkers17 investigated the effects of IL-1 in
an isolated perfused rat lung. These studies must also be
interpreted carefully because although increased IL-1 pro-
tein and mRNA expression was seen with ischemia and
reperfusion, a functional role was not identified. Ultimately,
there has not been a precise delineation of the functional
roles of TNF- and IL-1 in an intact animal model of
ischemia and reperfusion.
Despite the similar physiologic effects of TNF- and
IL-1, the combined blockade of these 2 mediators might
afford more protection than blockade of either cytokine
individually. Studies done in immune complex-induced
lung injury suggest that the effects of combined blockade of
TNF- and IL-1 are additive.18 Studies of combined cy-
tokine blockade have not been done in lung ischemia-
reperfusion injury, and information on such effects would
be novel.
Studies of patients with adult respiratory distress syn-
drome19 and those that have recently undergone lung trans-
plantation20 demonstrate increased locoregional expression
of TNF- and IL-1. This expression is thought to be
functionally important, and therefore animal studies detail-
ing blockade of these cytokines would be clinically rele-
vant. These studies seek to delineate the functional role of
TNF- and IL-1 and to investigate the mechanism of their
action individually and in combination during direct lung
ischemia-reperfusion injury.
Materials and Methods
Reagents
Rabbit antibody to rat TNF-, rat IL-1, and nonspecific rabbit
IgG were purchased from PeproTech Inc (Rocky Hill, NJ). All
other reagents were purchased from Sigma Chemical Co (St Louis,
Mo) unless otherwise specified.
Animal Model
Pathogen-free adult male Long-Evans rats (Simonsen Laborato-
ries, Inc, Gilroy, Calif) weighing between 280 and 320 g were used
for all experiments. The University of Washington Animal Care
Committee approved all experimental protocols. Animals were
initially anesthetized with 30 to 35 mg of intraperitoneal pento-
barbital. Subsequently, they were shaved and prepped. A 14-gauge
angiocatheter was inserted into the trachea through a midline neck
incision and secured with a 4-0 braided suture. Animals were then
placed on a Harvard Rodent Ventilator (Harvard Apparatus Inc,
Holliston, Mass) with a standardized inspired oxygen content of
60%, a rate of 80 breaths/min, and a positive end-expiratory
pressure of 2 cm H2O. Maximal peak pressures were maintained at
less than 10 cm H20. All animals received 0.4 mg of atropine
intramuscularly after being connected to the ventilator to maintain
their heart rates during anesthesia. Dissection was conducted by
using an operating microscope, and a warming blanket was placed
underneath the animals throughout the experiment. The animals
were placed on the right side, and a left posterior lateral thoracot-
omy in the fifth intercostal space was performed. The left lung was
mobilized atraumatically, and the inferior pulmonary ligament was
divided sharply. At this time, all animals received 50 units of
heparin dissolved in saline solution (total volume, 500 L). Five
minutes after the heparin was administered, the pulmonary hilum
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was occluded (inflated) with a noncrushing microvascular clamp.
During the experiment, the lungs were kept moist with periodic
application of warm normal saline solution, and covering the
incision with a plastic wrap minimized evaporative losses. The
period of ischemia was constant at 90 minutes. At the end of the
ischemic period, the clamp was removed from the hilum, and the
lung was allowed to ventilate and reperfuse for periods of up to 4
hours. Animals were administered 0.5 mL of warm subcutaneous
saline solution per hour to maintain hydration during the experi-
ment. At the end of the reperfusion period, a midline incision from
the neck to the pubis was created to allow access to the chest and
abdominal cavities. Blood samples were obtained from the inferior
vena cava just before animals were killed. The heart-lung block
was rapidly excised, and the pulmonary circulation was flushed
through the main pulmonary artery with 20 mL of normal saline
solution. The lungs were then separated from mediastinal tissues
and analyzed as outlined below. Time-matched control animals
underwent the same procedure, except the microvascular clamp
was not applied to the hilum (sham thoracotomy alone).
Treated animals received polyclonal rabbit anti-rat TNF- an-
tibody, anti-rat IL-1 antibody (PeproTech), or both at either a low
dose of 0.5 mg or a higher dose of 1 mg to determine the effects
of TNF- and IL-1 on ischemia-reperfusion injury. An additional
group of animals received both anti-rat TNF- and anti-rat IL-1
antibody at the lower dose. Antibody was dissolved in 500 L of
sterile phosphate-buffered saline solution (PBS) just before admin-
istration. It was then injected through the penile vein 5 minutes
before removal of the vascular clamp from the hilum. Nonspecific
IgG was administered in the same manner.
Lung Permeability Index
To quantitate lung injury caused by ischemia and reperfusion, a
lung permeability index was measured in the following manner.
Iodine 125-radiolabeled bovine serum albumin (BSA) was ob-
tained from NEN Life Sciences (PerkinElmer Life Sciences,
Wellesley, Mass). Before use of the iodine 125-radiolabeled BSA
in vivo, serial dilutions were performed to obtain an activity of
approximately 800,000 cpm (counts per minute). This volume of
iodine 125-radiolabeled BSA, approximately 2 L of the stock
solution, was then brought to a final volume of 500 L in a 1%
BSA-PBS solution. Five minutes before removal of the hilar clamp
or at an equivalent time in sham animals, the iodine 125-radiola-
beled BSA mix was intravenously injected. Immediately before the
death of the animals, 1 mL of blood was drawn from the inferior
vena cava. The heart-lung block was then excised and flushed, as
described previously. The counts were then quantitated for the left
and right lungs, as well as the inferior vena caval blood with a
gamma counter. The permeability index was then expressed as the
ratio of the counts per minute in the left lung to the counts in 1 mL
of inferior vena caval blood as follows:
Permeability index  Left lung (cpm)/1.0 mL of IVC blood (cpm)
This ratio was corrected for any variation in systemic distribution
of radioactivity and provided a reproducible measure of lung
microvascular permeability.
Myeloperoxidase Assay
The myeloperoxidase (MPO) assay was used to quantitate tissue
neutrophil accumulation in the lung. Lungs for MPO analysis were
harvested in a manner similar to that described above. The lungs
were homogenized for 60 seconds in a solution of 0.5% hexade-
cyltrimethylammonium bromide and 5 mmol/L ethelynediamine
tetraacetic acid in 50 mmol/L potassium phosphate buffer (pH
6.0). Samples were then ultrasonicated for 40 seconds in four
10-second bursts. The homogenized tissue was maintained on ice
between all tissue processing periods. Samples were then centri-
fuged at 2300 rpm for 30 minutes at 4°C. The assay buffer was
composed of 0.0005% H2O2 and 0.167 mol/L o-dianisidine dihy-
drochloride in 100 mmol/L potassium phosphate buffer (pH 6.0).
Fifty microliters of each sample was mixed with 1.45 mL of assay
buffer, and the change in absorbance at 460 nm over 1 minute was
recorded. Results of the MPO assay are recorded as the change in
absorbance over 1 minute at 460 nm.
Bronchoalveolar Lavage
Additional animals underwent bronchoalveolar lavage (BAL) at
the time of death; the heart-lung block was not flushed. With the
use of the 14-gauge angiocatheter placed for ventilation, the lungs
underwent lavage individually with 3 mL of cold sterile saline
solution. The contralateral hilum was clamped to facilitate indi-
vidual lung BAL analysis. At least 80% of the instilled fluid was
recovered from each lung BAL fluid sample. This fluid was cen-
trifuged (1500 rpm  8 minutes at 4°C) to pellet the cells in the
lavage fluid. The pellet was resuspended in 10 mL of sterile water
to lyse red blood cells. This fluid was again centrifuged (1500
rpm  8 minutes at 4°C). The supernatant was discarded, and the
cells were counted with a hemacytometer (Hausser Scientific Co,
Horsham, Pa).
Western Blot Analysis
Lung tissue was homogenized in 10 mL of solution containing 10
mmol/L N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (pH
7.9), 150 mmol/L NaCl, 1 mmol/L ethylenediamine tetraacetic
acid, 0.5 mol/L phenylmethylsulfonyl fluoride, 0.6% NP-40, and a
protease inhibitor cocktail (50 L of a 1000 mixture). The
homogenate was incubated on ice for 5 minutes, and 1-mL aliquots
were placed into microfuge tubes for analysis. The remaining
sample was stored as whole-cell lysates at 4°C. Samples were
centrifuged at 14,000 rpm for 10 minutes at 4°C. The pellet was
discarded, and the supernatant protein concentration was deter-
mined by using the bicinchoninic assay (Pierce Biotechnology,
Inc, Rockford, Ill). Approximately 40 g of protein were loaded
on sodium dodecylsulfate-polyacrylamide gel electrophoresis gels
(12%) and run at 100 V for 2 hours. After transfer to a polyvi-
nylidene difluoride membrane, the membrane was stained with
Coomasie blue to determine equal protein transfer. The mem-
branes were then incubated with either anti-IL-1 or anti-TNF-
polyclonal antibody (PeproTech) at 1:1000 dilution overnight. A
horseradish peroxidase-conjugated secondary antibody was ap-
plied for 1 hour, and the proteins were visualized with Pierce
SuperSignal reagents (Pierce Chemical Company, Rockford, Ill)
and autoradiography.
Ribonuclease Protection Assay
Lung RNA was isolated in guanidine thiocyanate, with 2 rounds of
acid phenol-chloroform extraction and alcohol precipitation. RNA
integrity was confirmed by means of agarose gel electrophoresis
Krishnadasan et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 2 263
G
TS
and quantitated by means of optical density measurements (260
nm). RNA from each rat was evaluated with the Riboquant system
(BD Biosciences Pharmingen, San Diego, Calif); rat template
rCK1 was used for detection of cytokines. In vitro transcription
was carried out in transcription buffer supplemented with (-32P)
uridine triphosphate (3000 Ci/mmol, Amersham Biosciences, Pis-
cataway, NJ) and T7 RNA polymerase. After DNAase I treatment,
the riboprobe was isolated by means of phenol-chloroform extrac-
tion and ammonium acetate-ethanol precipitation, and labeling
efficiency was determined by measuring Chernokov activity in a
scintillation counter. Each riboprobe was diluted to the optimal
activity defined by the manufacturer, added to 20 g of kidney
RNA, heated to 90°C, allowed to cool to 56°C, and annealed
overnight. After RNase and proteinase K treatment, protected
RNA hybrids were purified by means of phenol-chloroform ex-
traction and ammonium acetate-ethanol precipitation and sepa-
rated by means of electrophoresis on 5% polyacrylamide/8M urea
gels. Gels were dried and subjected to autoradiography by using
Kodak Biomax MS2 film (Eastman Kodak Company, Rochester,
NY).
Immunohistochemistry
Whole-lung tissue specimens were immediately fixed in 10%
neutral-buffered formalin. Tissue samples were dehydrated
through a series of graded alcohol baths, cleared, infiltrated, and
embedded in paraffin. Specimens were cut in 5-m serial sections,
baked overnight at 50°C, and archived. In preparation for immu-
nocytochemistry, sections were dewaxed and rehydrated through
exposure to graded baths to a final distilled water wash. Specimens
were then blocked with 5% normal serum for 30 minutes at 37°C.
After the blocking step, excess serum was removed, and the
primary antibody was applied at the concentration predetermined
by means of titration experiments. The primary antibody (8 g/
mL, PeproTech) was incubated for 1 hour at 37°C. After incuba-
tion, sections were rinsed 3 times in 1 PBS (pH 7.4). Manufac-
turer stock secondary antibody (Vector Laboratories, Burlingame,
Calif) was then applied at a dilution of 1:250 and incubated for 30
minutes at 37°C. At this time, the Avidin-Biotin complex, ABC
conjugate (Elite kit, Vector Laboratories), was made a minimum of
30 minutes before use. After the secondary antibody incubation,
sections were rinsed 3 times, and the ABC conjugate (Vector
Laboratories) was then applied to the sections. Staining was per-
formed with diaminobenzidine tetrahydrochloride. Sections were
then rinsed in running tap water for 10 minutes, dehydrated,
cleared, and mounted with permanent mounting media. Stained
sections were examined by using the image analysis software
Image Pro Plus (Media Cybernetics, Silver Spring, Md). Ten
random fields were acquired by using digital photography. Anal-
ysis was automated by calibrating and establishing a threshold for
positive staining on the basis of intensity and a value acquired by
the software representing a total area per field. Values for total
areas were then averaged, and therefore comparisons among con-
trol values and experimental samples were performed.
Statistical Analysis
All data were presented as mean values  SEM unless otherwise
designated. Comparisons between multiple groups were made by
using analysis of variance and within groups by using the Bonfer-
roni or Dunnett modified 2-tailed t test.
Results
Changes in Lung Vascular Permeability
Four different groups of control animals were generated.
Negative control animals were those that did not undergo
any surgical manipulation. Sham thoracotomy-only control
animals were connected to the ventilator and had a left
thoracotomy and up to 5.5 hours of mechanical ventilation.
A third group underwent thoracotomy and occlusion of the
left hilum for 90 minutes. These animals were killed before
any reperfusion. The final group was subjected to the full
protocol, including 90 minutes of ischemia, followed by 4
hours of reperfusion (Figure 1). The permeability index in
animals undergoing thoracotomy alone (0.18  0.02) was
double that seen in unmanipulated lungs (0.09  0.006).
The increase in permeability seen with thoracotomy and
ventilation was statistically significant (P  .001). The
difference in permeability between animals that underwent
thoracotomy alone and those that were subjected to 90
minutes of ischemia without reperfusion was not statisti-
cally significant (0.18  0.02 vs 0.22  0.005, P  .20). A
7-fold increase in permeability was seen in animals that
underwent 4 hours of reperfusion after 90 minutes of isch-
emia (0.75  0.01). The difference in lung permeability
index between unmanipulated control animals or those un-
dergoing ischemia alone and those undergoing ischemia and
reperfusion were highly statistically significant (P  .001).
There was no statistically significant difference in per-
meability values for positive control animals receiving PBS
(0.75  0.01) or nonspecific IgG (0.77  0.02, Figure 2).
Animals receiving antibody to TNF- or IL-1 had a sig-
nificant decrease in permeability at 4 hours of reperfusion
when compared with that of positive control animals (per-
meability index of 0.43  0.05 and 0.45  0.02, respec-
tively). This represented a 48.7% and 47.4% decrease in
injury among those animals receiving antibody (0.5 mg) to
TNF- or IL-1, respectively (P  .001). The higher dose
of blockade of IL-1 correlated with a 61.6% reduction in
vascular injury (0.34  0.02, P  .001). However, admin-
istration of the higher dose of TNF- (1 mg) did not
significantly alter the protection seen at the lower dose
(45%). The combined blockade of both cytokines decreased
lung vascular injury by 71%, which was more protection
than that afforded by blockade of either TNF- or IL-1 in
isolation (P  .001).
MPO Activity
MPO activity was measured in lungs from unmanipulated
control animals and from animals subjected to 90 minutes of
ischemia and 0, 1, 2, 3, and 4 hours of reperfusion (Figure
3). The change in absorbance at 460 nm in unmanipulated
control animals was 0.061  0.002. With ischemia only,
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MPO activity increased only slightly when compared with
that in unmanipulated control animals (P  .03). Reperfu-
sion was associated with a steady increase in MPO activity
that was detectable at 2 hours and markedly increased by 3
hours (0.26  0.01) and 4 hours (0.41  0.04) after reper-
fusion (P  .001, Figure 3). MPO content appeared to peak
after 4 hours of reperfusion.
Animals receiving antibody to TNF- and IL-1 had
statistically significant decreases in MPO activity at 4 hours
of reperfusion when compared with that in positive control
animals (0.33  0.03 for TNF- and 0.30  0.02 for IL-1
vs 0.46  0.01, P  .01, Figure 4). The decrease in MPO
content associated with TNF- and IL-1 blockade corre-
lated with a 30.9% and 38.5% decrease in tissue neutrophil
Figure 1. Left lung permeability in control animals. The lung permeability index is defined as counts per minute in
the left lung divided by counts per minute in 1 mL of inferior vena caval blood. There is a 7-fold increase in lung
vascular permeability in animals that undergo ischemia and reperfusion when compared with unmanipulated
animals (P < .001). Animals that underwent thoracotomy alone and ischemia alone also had a statistically
significant increase in permeability compared with that in unmanipulated control animals (P < .04; n  4 in all
experimental groups).
Figure 2. Left lung permeability in treated animals. Animals receiving anti-TNF-, anti-IL-1 (0.5 mg), and combined
blockade demonstrated a statistically significant decrease in lung vascular injury. Two groups of positive control
animals are shown, one receiving saline solution and one receiving nonspecific rabbit IgG. There is no difference
in permeability between these 2 groups. Animals that were administered anti-TNF- and anti-IL-1 antibody (0.5
mg) demonstrated a 48.7% and 47.4% decrease, respectively, in lung vascular injury compared with that seen in
control animals. Animals that received combined blockade demonstrated a 71% decrease in injury, which was
statistically greater protection than that afforded by blockade of either cytokine alone (n > 3 in all experimental
groups).
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accumulation, respectively. Combined blockade with anti-
body to both cytokines decreased MPO content by 52.4%, a
decrease in tissue neutrophil accumulation that was greater
than that seen with individual cytokine blockade (P .002).
BAL Neutrophil Content
BAL analysis was undertaken to evaluate neutrophil content
in the distal airways and alveolar compartment. Baseline
BAL neutrophil counts were recorded in 4 groups: unma-
nipulated control, sham thoracotomy alone, 90 minutes of
ischemia alone, and 90 minutes of ischemia followed by 4
hours of reperfusion (Figure 5). Animals undergoing sham
thoracotomy or ischemia alone did not demonstrate a sig-
nificant increase in BAL neutrophil content; however, a
statistically significant increase in BAL neutrophil content
was seen with 4 hours of reperfusion (P  .005). The
predominant cell type after 4 hours of reperfusion was the
neutrophil, whereas all the other groups demonstrated
mainly alveolar macrophages (95%).
In animals treated with antibody to TNF- and IL-1,
there was a statistically significant decrease in cell count in
comparison with the 4-hour positive control animals (P 
.011, Figure 6). This decrease in alveolar compartment
cellular accumulation represented a 46% and 35.8% de-
crease in TNF- and IL-1 antibody-treated animals, re-
spectively.
Western Blot Analysis of TNF- and IL-1
TNF- protein was not detected in the left lung homoge-
nates of unmanipulated negative control animals, but pro-
tein was detected within 1 hour of reperfusion (Figure 7).
The expression of TNF- appeared to peak at 2 hours, as
seen in the densitometric analysis shown below and then
decrease to a baseline expression at 3 and 4 hours. IL-1
Figure 3. MPO content in control animals. MPO is measured as the change in absorbance at 460 nm over 1 minute.
There is a steady increase in MPO content in the left lungs with increasing time of reperfusion. The increase in
MPO content at 4 hours was statistically different from that of unmanipulated control animals (P < .001). Each
experimental group includes 4 animals.
Figure 4. MPO in treated animals. Tissue neutrophil accumulation was decreased in animals receiving anti-TNF-
and anti-IL-1 antibody (P < .04). Animals that were administered antibody to both TNF- and IL-1 demonstrated
a 52.4% decrease in MPO content (P < .002, n > 3 in all experimental groups).
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protein was not detectable in the negative control left lung
homogenates (Figure 8). There was a slight amount of
IL-1 detected at 1 and 2 hours of reperfusion that increased
significantly at 3 hours and peaked at 4 hours. The densi-
tometric analysis, quantitating the increased expression of
IL-1 late during reperfusion, is shown below. The later
expression of IL-1 contrasts with the earlier expression of
TNF-. This early appearance of TNF- supports the im-
plication that it regulates expression of other proinflamma-
tory cytokines and effects neutrophil recruitment as early as
1 to 2 hours after reperfusion.
Ribonuclease Protection Assay
Ribonuclease protection assays were performed on lung
extracts from 3 experimental groups: animals that under-
went 90 minutes of ischemia and 3 hours of reperfusion and
animals similarly treated but also receiving either anti-
TNF- antibody or anti-IL-1 antibody. Both left and right
lungs were evaluated in all experimental groups (Figure 9).
Animals that underwent ischemia and reperfusion of the left
lung demonstrated significantly increased mRNA expres-
sion for a variety of mediators (IL-3, IL-5, IL-1, TNF-,
IL-2, and interferon ). In reperfused lungs from animals
treated with anti-TNF- antibody, there was decreased ex-
pression of all inflammatory and regulatory cytokines com-
pared with that seen in positive control lungs. This effect
was most pronounced for IL-2, IL-4, IL-10, and TNF-
mRNA. Lung tissue treated with antibody to IL-1 also
demonstrated a decreased expression of cytokine mRNA
compared with that seen in tissue from positive control
animals. Densitometric analysis for positive control and
treated animals is shown in Figure 10. In a separate exper-
iment, inhibition of the transcription factor nuclear factor
B with calcineurin inhibitors resulted in diminished ap-
Figure 5. BAL cell count increased significantly in those animals undergoing ischemia followed by reperfusion
compared with that in unmanipulated control animals (P < .005). A small increase in the cell count was seen with
thoracotomy alone and ischemia alone (P  not significant). The predominant cell type in the unmanipulated
animals was the alveolar macrophage, and the majority of the cells in the reperfused lungs were neutrophils (n 
4 in all experimental groups).
Figure 6. BAL cell count in treated animals. A significant decrease in alveolar leukocyte sequestration was also
noted in animals receiving anti-TNF- or anti-IL-1 antibody (P < .02, n  4 in all experimental groups).
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pearance of mRNA for TNF-, but not IL-1, in injured
lungs. This suggests a potential divergence of mechanism of
transcriptional regulation for these 2 cytokines (submitted
manuscript).
Immunocytochemistry Analysis
Immunohistochemistry analysis data are shown in Figure
11. Surgical control and injured left lungs were processed
for immunohistochemical analysis. A time course of injured
lungs, including those that underwent ischemia alone and
reperfusion of 15, 30, 60, 120, and 360 minutes, were
stained for either TNF- or IL-1. In animals with negative
assay results and surgical control animals, minimal staining
was detected. Positive staining for TNF- and IL-1 was
present at the end of ischemia but became much more
Figure 7. Western blot analysis of left lung homogenates for TNF-. The molecular weight (MW) marker is shown
in the far left lane. There is no detectable TNF- protein in the negative control group. Protein is detected at 1 hour,
peaks at 2 hours, and returns to a baseline level at 3 and 4 hours of reperfusion. Densitometric analysis of these
differences is shown below (Western blots done in triplicate).
Figure 8. Western blot analysis of left lung homogenates for IL-1. The molecular weight (MW) marker is shown
in the far left lane. There is no detectable IL-1 protein in the negative control group. A small amount of protein
is detected at 1 and 2 hours of reperfusion. At 3 hours, there is increased IL-1 detected, which peaks at 4 hours.
Densitometric analysis is shown below (Western blots done in triplicate).
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intense within 15 minutes of reperfusion. In both TNF--
and IL-1-stained sections, staining was initially localized
to lung macrophages. At later time points, TNF- was
detected in a more diffuse parenchymal pattern, but IL-1
remained localized to the macrophage throughout. How-
ever, the distribution of positively stained macrophages for
IL-1 changed from those predominantly localized around
the vasculature early in reperfusion to both interstitial and
alveolar macrophages late in reperfusion.
Discussion
A precise delineation of the functional roles of TNF- and
IL-1 in an intact animal model of lung ischemia-reperfu-
sion injury has not been previously elucidated. Vascular
permeability studies demonstrate that blockade of both cy-
tokines individually provided significant protective effects
at 4 hours. The protection afforded by TNF- blockade
decreased lung vascular injury by 49%. Other studies have
indicated slightly different degrees of protection associated
with TNF- antagonism. These differences in protection
might be explained by the variability in the reported per-
meability of positive control animals in previously pub-
lished experiments.16,21,22 Studies of nonischemic inflam-
matory injury indicate that the protection afforded by TNF
blockade is between 40% and 67%. These results are con-
sistent with the degree of protection seen in our model of
reperfusion injury.13,18 IL-1 blockade has not been studied
in an intact model of lung ischemia-reperfusion injury.
Isolated perfused rabbit lungs demonstrated increased IL-1
mRNA and protein with reperfusion.17 In this study the
effects of IL-1 blockade on lung vascular permeability
were less dramatic at the lower dose than those seen with
TNF- blockade; the protection afforded was 30%. How-
ever, with the higher dose, IL-1 blockade produce a more
profound effect than TNF- antagonism. Other studies have
demonstrated that the effects of IL-1 antagonism are less
significant than those seen with TNF- antagonism.7,13,18
This apparent difference might be explained in part by the
dose used in this study.
Combined blockade with antibody to both of these cy-
tokines was protective in an additive fashion. This might not
seem intuitive because both of these cytokines have similar
physiologic effects, but other investigators have also dem-
onstrated an additive effect related to combined blockade in
neutrophil-dependent models.23 The effects of combined
blockade were statistically more protective than either
TNF- or IL-1 blockade in isolation, which suggests that
although these 2 cytokines have similar proinflammatory
effects, the mechanism by which they effect injury might be
different. TNF- mRNA appears to be under a different
transcriptional regulation than IL-1, and therefore its func-
tions might not be so redundant.
Neutrophil recruitment and subsequent neutrophil-medi-
ated damage is well characterized in lung ischemia-reper-
fusion injury.21 Both TNF- and IL-1 increase the expres-
sion of selectins and cellular adhesion molecules and direct
neutrophil chemotaxis through direct effects and through
the production of chemokines.24 As expected, blockade of
these 2 cytokines was associated with a decrease in tissue
(MPO content) and alveolar (BAL cell count) cell content.
Decreases in MPO content of 36% and 40% were demon-
strated with anti-TNF- and anti-IL-1 antibody. Others
have also correlated a decrease in MPO content with a
blockade of these 2 cytokines.7,18 Combined blockade of
both cytokines decreased MPO content by 49%, and this is
the first report of combined blockade of TNF- and IL-1
resulting in an additive effect on neutrophil recruitment.
These assays demonstrate that the proinflammatory effects
of TNF- and IL-1 are mediated at least partially through
neutrophil recruitment and activation. Combined blockade
of these 2 mediators is additive, suggesting that the mech-
anisms by which these 2 cytokines effect neutrophil recruit-
ment might be distinct.
Figure 9. Ribonuclease protection assay. Three experimental
groups are shown. The left and right lungs of the positive control
are shown in the far left lanes. The adjacent lanes represent the
left and right lungs of animals that underwent ischemia, 4 hours
of reperfusion, and treatment with anti- TNF- or anti-IL-1
antibody. There is a generalized decrease in expression of cyto-
kines receiving antibody to TNF- and IL-1 (ribonuclease pro-
tection assay done in triplicate).
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Figure 10. Densitometric analysis for a select group of cytokine mRNAs. By using Image J software and calibrating
appropriately for gray scale, a decreased expression of message for TNF-, IL-2, IL-1, interferon , IL-4, and IL-10
are shown in response to TNF- and IL-1 blockade. Ab, Antibody.
Figure 11. Immunohistochemical sections of lungs stained for TNF- and IL-1 (representative samples, immuno-
histochemistry done on 3 different specimens per group). A and C, Negative surgical control demonstrating minimal
staining for TNF- and IL-1, respectively; C and D, sections from injured lungs after 90 minutes of ischemia and
15 minutes of reperfusion showing intense positive brown staining for TNF- and IL-1, respectively, in
mononuclear cells (arrows).
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Western blots of left lung homogenates probing for
TNF- activity detects the production of TNF- protein
after 1 hour of reperfusion. Detectable protein levels was
not evident in the negative control lungs. TNF- protein
appears at 1 hour, peaks at 2 hours, and then returns to
baseline production at 3 and 4 hours of reperfusion. A
precise delineation of TNF- protein expression has not
been elucidated in lung inflammation or lung ischemia-
reperfusion injury. Early expression of TNF- protein has
been demonstrated in other models of reperfusion,2,4,6 as
well as in clinical situations involving lung reperfusion.20
The mechanism affecting the early expression of TNF-
protein is still unclear, but some investigators have sug-
gested that the early expression might represent the trans-
lation of constitutively expressed TNF- mRNA.25 Confir-
mation of this hypothesis would require the demonstration
of new TNF- protein in the presence of transcriptional
blockade during ischemia and reperfusion.
Immunohistochemical analysis detects TNF- protein
within 15 minutes of reperfusion. Immunohistochemistry is
a more sensitive modality for detecting small quantities of
protein. The early expression of TNF- from alveolar mac-
rophages suggests that this cell is the key effector cell
driving injury early after reperfusion. Later, during reper-
fusion, there is more diffuse expression of this cytokine
throughout the parenchyma.
Expression of IL-1 protein is not detected in negative
control left lungs (Western blot). Significant expression is
detected in the injured lungs, which peaks after 3 hours of
reperfusion; however, expression of IL-1 is seen soon after
reperfusion in the immunohistochemical analysis. This
again reveals the higher sensitivity of the histochemical
analysis when compared with Western blotting. The expres-
sion of IL-1 appears to be less diffuse than TNF-. IL-1
expression appears to be localized to macrophages. It does
appear that the expression of IL-1 increases with reperfu-
sion, thus explaining the detection of the protein in the
Western blot later during injury.
Blockade of TNF- demonstrates a blunting of the ex-
pression of the majority of cytokine mRNAs investigated on
the ribonuclease protection assay shown. Not only are the
expression of proinflammatory cytokines, such as IL-1,
IL-2, and interferon , decreased, but the expression of
regulatory cytokines IL-4 and IL-10 are also blunted. The
same pattern of reduced message expression is also evident
in the left lungs that received anti IL-1 antibody, although
the effects are not as pronounced. The expression of collat-
eral cytokine mRNA has not been investigated in lung
ischemia-reperfusion injury, and these effects suggest that
the protective effects of TNF- and IL-1 blockade are also
mediated in part through a diminution in expression of
phlogistic cytokine mRNA.
TNF- and IL-1 appear to play functional roles in
warm lung ischemia and reperfusion. This is demonstrated
through a decrease in lung injury (permeability, MPO, and
BAL), as well as a modulation of cytokine expression
(ribonuclease protection assay). Both TNF- and IL-1 are
expressed early during reperfusion (Western blot), and com-
bined blockade of both of these cytokines appears to be
additive.
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